Amgen Launches $239 Repatha Direct-to-Patient Program

On Oct. 6 Amgen launched AmgenNow, a U.S. direct-to-patient program offering its cholesterol drug Repatha (evolocumab) for $239 per month — roughly a 60% discount versus the current U.S. list price. The program is open to eligible patients, including the uninsured and Medicare/Medicaid beneficiaries, will not process insurance or require step therapy or prior authorization, and is designed to bypass traditional insurance channels. Amgen says the cash price matches the lowest it now receives in any G-7 country and is offering the program in support of the Trump administration’s push to lower drug costs, with plans to make AmgenNow accessible via the TrumpRx platform. Other companies and platforms (including GoodRx, Pfizer and AstraZeneca initiatives) have offered similar discounts or price matches as drugmakers respond to federal pressure to align U.S. prices with lower international rates. Repatha generated about $2.2 billion in sales last year; Amgen also cited positive VESALIUS-CV trial results showing reduced major adverse cardiovascular events and said it is continuing to expand U.S. manufacturing capacity.